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Abstract 
Glucagonomas  are  pancreatic  islet  cell
tumors  arising  from  the  alpha  cells  which
belong  to  neuroendocrine  tumors.  They  fre-
quently metastasize to the liver. We report the
case of a 52- year old man with a pancreatic
glucagonoma with synchronous multiple liver
metastases  treated  by  surgery,  transarterial
chemoembolization,  percutaneous  radiofre-
quency  thermal  ablation  and  long-acting
octreotide. Our report confirms that a multi-
modal  approach  is  very  effective  in  patients
with unresectable liver metastases from pan-
creatic endocrine tumors providing long-last-
ing palliation and probably prolonging survival.    
Case Report
A 52-year old man was referred to our hospi-
tal  because  of  weight  loss,  chronic  diarrhea
and an erythematous rash with bullae and ero-
sions on the feet (Figure 1), in the groin and
on the face. Blood chemical analyses showed
mild anemia (hemoglobin 10.8 g/dL), and an
impaired fasting glucose test. As a part of the
diagnostic work-up, he underwent an abdomi-
nal  computed  tomography  which  showed  a
large tumor of the pancreatic tail and multiple
hepatic lesions (Figure 2). Histological exami-
nation of a specimen obtained by ultrasound-
guided percutaneous biopsy of a liver lesion
revealed a tubulo-acinar structure of moder-
ately atypical cells positive for chromogranin
(Figure 3). 111In-octreotide scan showed hepat-
ic and pancreatic uptake without evidence of
extrahepatic  metastases.  A  high  level  of
glucagon in the plasma (950 pg/mL) confirmed
the  diagnosis  of  glucagonoma.  Long-acting
octreotide  was  started  with  partial  improve-
ment of the symptoms. The patient was then
treated  with  hepatic  transarterial  chemoem-
bolization  (TACE)  combined  with  percuta-
neous radiofrequency thermal ablation (RFTA)
in an effort to reduce the hepatic tumor bur-
den. Two sessions of TACE, one month apart,
were performed using polyvinyl alcohol-based
microspheres (DC Bead™, Biocompatibles UK
Ltd., Farnham, UK) pre-loaded with 100 mg of
doxorubicin. One day after each TACE proce-
dure we performed ultrasound guided percuta-
neous radiofrequency. The radiofrequency sys-
tem consists of an expandable electrode with
insulated outer needle of 2.2 mm of diameter
that  houses  nine  deployable  curved  tines
(Starburst  XL;  Rita  Medical  Systems).
Abdominal  enhanced  CT  scan  at  one  month
after the last RFTA procedure showed minimal
arterial contrast enhancement in two lesions
of the right lobe. The pancreatic tumor was
then surgically removed and the residual vital
hepatic tumors were treated with four sessions
of  radiotherapy  with  Y-DOTATOC,  a  radiola-
beled somatostatin analog. Thirty-two months
after diagnosis the patient was well, he had
regained his normal body weight and the ery-
thema had completely disappeared. 
Discussion
Glucagonomas  are  pancreatic  islet  cell
tumors  arising  from  the  alpha  cells  which
often  produce  elevated  levels  of  circulating
glucagon.
1 The  characteristic  feature  of  the
glucagonoma syndrome is a skin rash termed
necrolytic migratory erythema. Other findings
include a mild insulin-resistant diabetes, glos-
sitis, cheilosis, weight loss, venous thrombosis
constipation and mood changes.
2Glucagonoma
is a neuroendocrine tumor (NET) which fre-
quently metastasize to the liver.
3The particular
biological behavior of NETs, characterized by a
long natural history, even in the presence of
liver  metastases,  has  important  therapeutic
implications.
4,5 Surgical resection is to be con-
sidered  when  the  metastases  are  resectable
and  no  extrahepatic  disease  is  present.
Unfortunately, neuroendocrine metastases are
usually multiple and diffuse and therefore rad-
ical  resection  is  feasible  only  in  10-20%  of
patients.
6 Surgical  resection  of  liver  metas-
tases with curative intent is associated with 5-
year survival rates of 73-85%
7,8 but, in unre-
sectable disease, surgery is not useful as a pal-
liative tool unless more than 90% of the tumor
load can be debulked.
9 In this setting, systemic
chemotherapy and octeotide have proved more
useful  in  controlling  the  endocrine  syn-
drome.
10,11 On the experience of the efficacy of
transarterial  chemoembolization  (TACE)  in
hepatocellular carcinoma that shares vascular
findings with neuroendocrine hepatic metas-
tases, TACE has been effectively used in the
palliative  management  of  these  tumors.
12-13
TACE has also been used in adjuvant settings
to reduce tumor load before hepatic resection,
hepatic transplantation or tumor ablation tech-
niques.
4,14,15 Preliminary results show that the
new drug-eluting microspheres now available
seem  to  optimize  TACE  procedures.  In  fact,
these microspheres are capable of loading the
drugs and slowly delivering them directly into
the tumor, thus achieving high intratumoral
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migratory erythema on
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concentrations  and  low  plasma  concentra-
tions.
16,17 The results with microspheres loaded
with doxorubicin have been promising, show-
ing an advantageous pharmacokinetic profile
and  good  clinical  response  when  compared
with conventional TACE both in patients with
unresectable HCC
18 and in patients with liver
metastases  from  well  differentiated  NETs.
19
Local therapy using RFTA provides a minimal-
ly invasive procedure that decreases tumor vol-
ume, preserves most of the normal liver and
can be repeated several times.
20 Nevertheless,
histological data from liver specimens of HCC
patients  who  underwent  RFTA  showed  that
tumor  size  has  a  significant  impact  on  the
local effect of this treatment. Indeed, vessels
adjacent to the tumor cause heat loss due to
perfusion-mediated cooling.
21 Balloon catheter
occlusion  or  TACE  increase  the  efficacy  of
RFTA by reducing tumor arterial supply.
22 In
our patient we performed each RFTA exactly
one day after the TACE to obtain an increase of
the necrotic area induced by thermal ablation.
After two procedures of both TACE and RFTA,
the  hepatic  tumor  load  was  considerably
reduced, so that we were then able to perform
four sessions of somatostatin receptor mediat-
ed radiotherapy using 90Y Tyr-octreotide, which
is  capable  of  binding  to  the  residual  vital
tumor. Our report confirms that a multimodal
approach  is  very  effective  in  patients  with
unresectable liver metastases from pancreatic
endocrine tumors providing long-lasting palli-
ation and probably prolonging survival. 
References
1. Friesen SR. Tumor of the endocrine pan-
creas. N Engl J Med 1982;306:580-90.
2. Mallinson CN, Bloom SR, Warin AP, et al. A
glucagonoma syndrome. Lancet 1974;2:1-5.
3. Plöckinger U, Rindi G, Arnold R, Eriksson
B, et al. Guidelines for the diagnosis and
treatment  of  neuroendocrine  gastroin-
testinal  tumours.  Neuroendocrinology
2004; 80:394-24.
4. Falconi M, Bassi C, Bonora A, et al. Role of
chemoembolization  in  synchronous  liver
metastases  from  pancreatic  endocrine
tumours. Dig Surg 1999;16:32-8.
5. Vogl TJ, Naguib NN, Zangos S, et al. Liver
metastases  of  neuroendocrine  carcino-
mas: interventional treatment via transar-
terial  embolization,  chemoembolization
and thermal ablation. Eur J Radiol 2009;
72:517-28.
6. Sarmiento  JM,  Que  FG.  Hepatic  surgery
for  metastases  from  neuroendocrine
tumors.  Surg  Oncol  Clin  N  Am  2003;12:
231-42.
7. Chamberlain RS, Canes D, Brown KT, et al.
Hepatic neuroendocrine metastases: does
intervention  alter  outcomes?  J  Am  Coll
Surg 2000;190:432-45.
8. Moertel CG, Johnson CM, McKusick MA, et
al.  The  management  of  patients  with
advanced carcinoid tumors and islet cell
carcinomas.  Ann  Intern  Med  1994;120:
302-9.
9. Blonski WC, Reddy KR, Shaked A, et al.
Liver transplantation for metastatic neu-
roendocrine  tumor:  a  case  report  and
review  of  the  literature.  World  J
Gastroenterol 2005;11:7676-83.
10. Öberg K. The use of chemotherapy in the
management  of  neuroendocrine  tumors.
Endocrinol  Metab  Clin  North  Am  1999;
22:941-52.
11. Saltz L, Trochanowski B, Buckley M, et al.
Octreotide as an antineoplastic agent in
the treatment of functional and nonfunc-
tional  neuroendocrine  tumors.  Cancer
1993;72:244-8.
12. Marlink RG, Lokich JJ, Robins JR, Clouse
ME.  Hepatic  arterial  embolization  for
metastatic  hormone-secreting  tumors.
Technique,  effectiveness,  and  complica-
tions. Cancer 1990;65:2227-32.
13. Ruszniewski P, Rougier P, Roche A, et al.
Hepatic  arterial  chemoembolization  in
patients  with  liver  metastases  of
endocrine tumors. A prospective phase II
study in 24 patients. Cancer 1993;71:2624-
30.
14. Roche  A,  Girish  BV,  de  Baère  T,  et  al.
Trans-catheter  arterial  chemoemboliza-
tion  as  firstline  treatment  for  hepatic
metastases  from  endocrine  tumors.  Eur
Radiol 2003;13:136-40.
15. Veenendaal LM, Borel Rinkes IH, Lips CJ,
van Hillegersberg R. Liver metastases of
neuroendocrine tumours; early reduction
of tumour load to improve life expectancy.
World J Surg Oncol 2006; 26:4-35.
16. Poggi  G,  Quaretti  P,  Minoia  C,  et  al.
Transhepatic  arterial  chemoembolization
with  oxaliplatin-eluting  microspheres
(OEM-TACE)  for  unresectable  hepatic
tumors. Anticancer Res 2008;28:3835-42.
17. Lewis  AL,  Taylor  RR,  Brenda  H,  et  al.
Pharmacokinetic and safety study of dox-
orubicin-eluting beads in a porcine model
of  hepatic  arterial  embolization.  J  Vasc
Interv Radiol. 2006;17:1335-43.
18. Varela  M,  Real  MI,  Burrel  M,  et  al.
Chemoembolization of hepatocellular car-
cinoma with drug eluting beads: efficacy
and  doxorubicin  pharmacokinetics.  J
Hepatol 2007;46:474-81.
19. de Baere T, Deschamps F, Teriitheau C, et
al.  Transarterial  chemoembolization  of
liver metastases from well differentiated
gastroenteropancreatic endocrine tumors
with  doxorubicin-eluting  beads:  prelimi-
nary  results.  J  Vasc  Interv  Radiol
2008;19:855-61.
20. Gillams  A,  Cassoni  A,  Conway  G,  et  al.
Case Report
Figure 2. Abdominal CT scan shows multi-
ple hepatic lesions.
Figure 3. Liver biop-
sy  reveals  a  tubu  lo-
acinar  structure  of
moderately  atypical
cells  positive  for
c h r o m o g r a n i n
(x100).Radiofrequency  ablation  of  neuroen-
docrine  liver  metastases:  the  Middlesex
experience. Abdom Imaging 2005;30:435-
41.
21. Lencioni R, Crocetti L, Petruzzi P, et al.
Doxorubicin-eluting  bead-enhanced
radiofrequency ablation of hepatocellular
carcinoma: a pilot clinical study. J Hepatol.
2008;49:217-22.
22. Rossi S, Garbagnati F, Lencioni R, et al.
Percutaneous  radio-frequency  thermal
ablation  of  nonresectable  hepatocellular
carcinoma after occlusion of tumor blood
supply Radiology 2000;217:119-26.
[Rare Tumors 2009; 1:e6] [page 15]
Case Report